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Abstract and Keywords  
Objective To assess whether cardiovascular events are increased after cessation of dual 
antiplatelet therapy (DAPT) following acute coronary syndrome and to explore predictors for 
recurrent events after DAPT cessation during long-term follow-up.  
Methods We did a retrospective observational cohort study. We included consecutive people 
with acute coronary syndrome (ACS) who were discharged from Scottish hospitals between 
January 2008 and December 2013 and who received DAPT after discharge followed by 
antiplatelet monotherapy. The rates of cardiovascular events were assessed during each 90-day 
period of DAPT treatment and 90-day period after stopping DAPT. Cardiovascular events were 
defined as a composite of death, ACS, transient ischaemic attack or stroke. Cox regression was 
used to identify predictors of cardiovascular events following DAPT cessation.  
Results 1340 patients were included (62% male, mean age 64.9(13.0) years). Cardiovascular 
events occurred in 15.7% (n=211) during the DAPT period (mean DAPT duration 175.1(155.3) 
days) and in 16.7% (n=188) following DAPT cessation (mean of 2.7 years follow-up).  
Independent predictors for a cardiovascular event following DAPT cessation were age (hazard 
ratio (HR) 1.07; 95% confidence interval (CI) 1.05-1.08; p<0.001), DAPT duration (HR 0.997; 
95% CI 0.995-0.998; p<0.001) and having revascularization therapy during the index admission 
(HR 0.58; 95% CI 0.39-0.85; p=0.005).  
Conclusions The rate of cardiovascular events was not significantly increased in the early period 
post DAPT cessation compared to later periods in this ACS population. Increasing age, DAPT 
duration and lack of revascularization therapy were associated with increased risk of 
cardiovascular events during long term follow up after DAPT cessation.  
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Key messages 
What is already known on this subject? 
Discontinuation of dual antiplatelet therapy (DAPT) is associated with an increased risk of 
cardiovascular disease in previous studies. The association between the duration of DAPT and 
DAPT cessation is unknown. 
What might this study add? 
We found that increasing age, DAPT duration and lack of revascularization therapy for the ACS 
were associated with increased risk of cardiovascular events during long term follow up after 
DAPT cessation. 
How might this impact on clinical practice? 
Our findings indicate that longer duration of DAPT and use of revascularization therapy may be 
related to a reduced risk of cardiovascular event after ACS and DAPT cessation.  
 
  
INTRODUCTION 
Antiplatelet therapy is indicated after an acute coronary syndrome (ACS) because it lowers 
mortality and reduces the early risk of recurrence. Dual antiplatelet therapy (DAPT), typically 
using aspirin and an ADP receptor antagonist such as clopidogrel, ticagrelor or prasugrel, is 
superior to use of a single antiplatelet agent. Clopidogrel, when given together with aspirin and 
fibrinolytic therapy has been shown to reduce the rate of death or re-infarction without major 
increased bleeding risk following ST-elevation myocardial infarction (STEMI) when compared 
with aspirin alone.1 2 Furthermore, patients with a non-STEMI ACS treated with both clopidogrel 
and aspirin had a lower rate of death from cardiovascular causes, non-fatal myocardial infarction 
or stroke than patients treated with aspirin alone.3 
 
Typically, DAPT is given for a defined period of time after which patients continue with 
antiplatelet monotherapy. There are reports that the risk of cardiovascular events increases after 
DAPT is stopped,4 5 perhaps due to a rebound in platelet activity.6 Studies have shown that use of 
DAPT beyond 12 months significantly reduces risk of cardiovascular events.7 8 Whether duration 
of DAPT is associated with risk of events after DAPT cessation is unclear. Most studies of risk 
after DAPT cessation also have short follow-up duration between 6 to 18 months,4 9 included 
predominantly male patients4 or patients with health insurance in specific health care plans.5 10 A 
better understanding of the long term outcomes after DAPT cessations and the predictors of 
events thereafter may help develop strategies to mitigate this risk. 
 
The National Health Service (NHS) Scotland has set up regional data Safe Havens which aim to 
facilitate rapid access to high quality health data for research purposes.11 We used data contained 
in NHS Greater Glasgow and Clyde (NHS GGC) Safe Haven to assess the incidence and 
predictors of cardiovascular events after discontinuation of DAPT in patients who have suffered 
ACS. We hypothesised that discontinuation of DAPT would increase the risk of cardiovascular 
events in the first 90 days interval after stopping DAPT. 
 
METHODS 
Study design 
We undertook a retrospective observational cohort study using healthcare records obtained from 
NHS Greater Glasgow and Clyde (GGC). NHS GGC is the largest health board in Scotland, 
serving a catchment area including the City of Glasgow, Inverclyde, Renfrewshire, East 
Renfrewshire, East Dunbartonshire and West Dunbartonshire. Approval was obtained from the 
NHSGGC Safe Haven advisory committee, which has approval from the West of Scotland 
Research Ethics Committee (GSH/13/CA/005). The study adhered to strict information 
governance and security protocols. All data are held within the NHSGGC Safe Haven with 
restricted access.  
 
Data source 
NHS GGC and the Robertson Centre for Biostatistics provide access to anonymised local 
healthcare data in the West of Scotland subject to the approvals described. We incorporated data 
from the Scottish Morbidity Record, the General Register Office for Scotland death registration 
records, the Prescribing Information System, the Scottish Care Information – Diabetes 
Collaboration (SCI-DC) and the General Practice database. The Scottish Morbidity Record 
database was used to search all admission for ACS that occurred in the West of Scotland from 
January 2008 through December 2013. 
 
Study setting and study population 
Patients were included in the study if they experienced an ACS, continued on DAPT following 
discharge (defined as cashing a prescription for DAPT within 60 days of hospital discharge) and 
subsequently stopped DAPT and then continued with single antiplatelet therapy. An ACS event 
was defined as emergency hospital admission with a main discharge diagnosis of ACS 
(International Classification of Diseases – Tenth revisions [ICD-10] codes I20, I21 or I22).  
 
Baseline demographic data were obtained from the Scottish Morbidity Record dataset. Medical 
history data were obtained from the General Practice and the Scottish Care Information – 
Diabetes Collaboration databases. These comorbidities were defined as a condition reported 
from general practitioners before the ACS event. A coronary revascularization procedure was 
defined as a procedure listed in operation field from Scottish Morbidity Record dataset during 
the index admission. Revascularization procedures include coronary artery bypass graft (English 
Office of Population Censuses and Surveys (OPCS-4) codes K40-46) and percutaneous coronary 
intervention (PCI) (OPCS-4 codes K49-50 and K75). 
 
DAPT use 
The usage of DAPT was identified and verified through the Prescribing Information System 
database. DAPT use included and combination of aspirin-clopidogrel, aspirin-dipyridamole, 
aspirin-ticagrelor and aspirin-prasugrel. The number of pills dispensed for each prescription was 
used to calculate the duration of DAPT use. In the primary analysis, the last day of DAPT use 
was based on the date of last DAPT prescription refill plus the number of days supplied for that 
refill. Discontinuation of DAPT was defined when there was no refill prescription or dispense 
date of DAPT more than 14 days after this date. 
 
Study endpoints 
The primary endpoint of the study was a cardiovascular event, which consists of composite of 
all-cause mortality, ACS (myocardial infarction (MI) or unstable angina), transient ischaemic 
attack or stroke after cessation of DAPT. Information on death was obtained through General 
Register Office for Scotland database. The ICD-10 codes were used to identified hospitalizations 
for ACS (I20 – I25), TIA (G458-G459) and stroke (I63-I64). The safety endpoint of the study 
was a major bleeding event following the first admission of ACS. Major bleedings were based 
on ICD-10 (I60-I62, H11.3, H31.3, H35.6, H43.1 and R58) 
 
Statistical methods 
Descriptive statistics are given for the whole population and separately for patients treated with 
medical or revascularization therapy for the index ACS. Categorical variables were summarised 
using frequencies and proportions and continuous variables as mean [standard deviation (SD)] or 
median [interquartile range (IQR)]. Patients were censored at the end of the follow-up period. 
 
The life table method was used to calculate unadjusted incidence rates per 1000 patient-days of 
the primary endpoint for each 90-day interval during DAPT and after DAPT cessation. Incidence 
rate ratios (IRR) with 95% confidence interval (95% CI) were calculated to compare incidence 
rates in medical and revascularization-treated patients during the same intervals.  
 
Poisson regression (or negative binomial if overdispersion was present) model was used to 
assess incidence of the primary endpoint after stopping DAPT. Incidence rate ratios were 
calculated with adjustment for age, medical or revascularization therapy and duration of DAPT. 
In these models, the risk of cardiovascular events in the first 90 days interval after stopping 
DAPT was compared with 91 to 180 days after stopping and with 91 to 360 days interval 
consistent with prior studies.4 5 Cox regression analysis was used to model the predictors of 
cardiovascular events after stopping DAPT. The models were adjusted for age, medical or 
revascularization therapy and duration of DAPT. Adjustment was not made for other risk factors 
such as hypertension, diabetes, hyperlipidaemia, chronic renal failure and ischaemic heart 
disease because of missing data. The proportional hazards assumption was tested by using of 
log-minus-log plots. We found no evidence of violation of this assumption. The adjusted 
hazard ratios (HRs) and 95% CI for cardiovascular event were estimated and adjusted to age, 
medical or revascularization therapy and duration of DAPT. The Harrell’s C-statistic result for 
the overall model prediction accuracy was reported. The Fine-Gray model for the 
competing risk of death was used as a sensitivity analysis12 and the sub-distribution hazard 
ratio (SHR) and 95% CI of SHR were estimated.  
 
Statistical analyses were performed using IBM SPSS Statistics version 21.013 and for competing 
risk analyses were performed using STATA version 15.0 (University of Glasgow). A value of 
p<0.05 was considered statistically significant. 
 
ROLE OF THE FUNDING SOURCE 
None. 
 
RESULTS 
Of the 7232 patients admitted with an ACS during the study period, 2899 (40%) patients 
received only single antiplatelet therapy, 1531 (21%) had no documented antiplatelet 
information leaving 2802 (38.7%) patients who were dispensed with DAPT. Of these 2802 
patients, 1872 patients were confirmed to refill a prescription for DAPT within 60 days of 
hospital discharge. Of these, 1340 (71.6%) had DAPT then continued with a single antiplatelet in 
the longer term and were (Figure 1) included in the study. Baseline characteristics are shown in 
Table 1. Mean follow-up after DAPT cessation was 1009 days, median 1067 days 
(supplementary figure). Following DAPT cessation, antiplatelet monotherapy with aspirin was 
commonly prescribed (79.1%), followed by clopidogrel (19.8%), then dipyridamole (0.6%) and 
ticagrelor (0.4%). 
 
Study endpoints 
Cardiovascular events occurred in 211 (15.7%) whilst taking DAPT, leaving1129 (84.3%) event-
free at DAPT cessation. After DAPT cessation 188 cardiovascular events occurred (16.7%) 
(Table 2). Major bleeding occurred in 6 (0.45%) and 5 (0.44%) while on DAPT and after DAPT 
cessation respectively. 
 
Cardiovascular events 
The incidence rate was higher in first 90-days of DAPT treatment compared to the following 90-
days of DAPT treatment (IRR, 5.73; 95% CI, 3.48-10.06; p<0.001) (Table 3). After cessation of 
DAPT, the incidence rate was not different in the first 90-days compared to the next 90-days 
(IRR, 0.65; 95% CI, 0.31-1.31; p=0.190). Medically-treated had a higher incidence of 
cardiovascular events during DAPT in the first 90-days (IRR, 2.57; 95% CI, 1.71-3.99; p<0.001) 
(Figure 2(a)) compared with revascularization-treated patients. After cessation of DAPT, there 
was no difference in the incidence rate of cardiovascular event between medically-treated 
patients and revascularization-treated patients in the first 90-day interval (IRR, 3.30; 95% CI, 
0.75-30.12; p=0.096) (Figure 2(b)). 
 
Adjusted incidence rate ratios following DAPT cessation 
After adjusting for age, medical or revascularization therapy and total duration of DAPT 
treatment, there was no increased risk of cardiovascular events in the first 90 days after DAPT 
cessation (adjusted IRR, 0.70; 95% CI, 0.32 to 1.55; p=0.375) compared to day 91-180 (Table 
4).  
 
Predictors of cardiovascular events following DAPT cessation 
The univariable and multivariable analysis of possible predictors of risk of cardiovascular 
events after stopping DAPT is presented in Table 5. Multivariable analysis of the Cox 
model, indicated that increased age (HR, 1.07; 95% CI, 1.05-1.08; p<0.001) was 
significantly associated with an increased risk of cardiovascular event, whereas patients 
treated with revascularization (HR, 0.58; 95% CI, 0.39-0.85; p=0.005) and longer duration 
of DAPT (HR, 0.997; 95% CI, 0.995-0.998; p<0.001) had lower risk (Harrell’s C 
statistic=0.77). Results were broadly consistent with Fine-Gray model. 
  
DISCUSSION 
We assessed the rate of cardiovascular events following DAPT cessation and explored predictors 
of events during long-term follow-up after DAPT cessation. The incidence was not higher in the 
first 90 days post DAPT cessation compared to later periods suggesting no rebound increase in 
risk in this population. Cardiovascular events did occur in the long-term follow period after 
DAPT cessation and we found that increasing age, lack of revascularization treatment for the 
ACS and duration of DAPT treatment to be independent predictors of cardiovascular event 
following DAPT cessation. 
 
The incidence of cardiovascular events following DAPT cessation in the literature varies between 
studies (4-17%). The incidence in the present study (16.7%) is at the higher end of this range and 
this could be due to longer follow-up period i.e. 2.7 year follow-up, which allowed us to capture 
more events. We did not see an increase in risk following DAPT cessation. This is in contrast to 
many other studies.4 5 10 14 There are several differences between our and other studies to note. 
These differences may be due to differences in definitions used of cardiovascular event between 
studies,15 and differences in the duration of DAPT after ACS (in the present study was 177 (155) 
days, which was shorter than previous studies).10 14 The shorter duration of DAPT in this study 
was 5.8 months and this is probably due to the recommendation made by the Cardiac 
Prescribing Group West of Scotland. This recommends 3 and 6 months of DAPT following 
a STEMI or NSTEMI, for use of bare metal stent and drug eluting stents respectively. More 
patients in our study were treated with medical therapy alone for their ACS 67% compared to 50% 
and 25% in the studies by Ho et.al.4 and Stephenson et.al.10  
 
We explored predictors of long-term events after DAPT cessation. We found that increasing age, 
DAPT duration and lack of revascularization therapy for the ACS were associated with increased 
risk of cardiovascular events after DAPT cessation. Previous studies have demonstrated that usage 
of clopidogrel for more than six months was associated with lower rates of death, myocardial 
infarction and/or stent thrombosis.16 17 These data suggest that ACS patients may benefit when the 
duration of DAPT is more than six months. In contrast, a network meta-analysis by D’Ascenzo 
et.al.18 found shorter DAPT duration (<12 months) is associated with lower rates of ischemic 
events in everolimus/zotarolimus eluting stents than bioresorbable stents. These data suggest 
that type of stent and DAPT duration may affect the cardiovascular events at follow-up.  
 
Strengths 
Our study had full information on antiplatelet use through the Prescribing Information System 
database. Thus, we were able to confirm that all patients included in this study were taking 
aspirin plus either clopidogrel or prasugrel or ticagrelor and which antiplatelet they took 
following DAPT cessation. This is in contrast to some previous studies where this information 
was not available.5 10 19  
 
We included ACS population in the West of Scotland. Ours is a study of all individuals in a 
community with an ACS identified through resources of the NHS GGC Safe Haven, regardless 
of sex and health care insurance. In previous studies, they only able to include predominantly 
male patients4 or patients with treated within a particular health care plan.5 10  
 
Study limitations 
Many patients with a diagnosis of ACS were not included in our analysis. This is because many 
received only single antiplatelet therapy, many did not continue receiving prescriptions for 
DAPT and many did not stop DAPT and then continue with antiplatelet monotherapy. There are 
several reasons for this. First, patients may be coded as an ACS in hospital records but not have 
met criteria for DAPT use. Patients who did not receive a further prescription for DAPT within 
60 days of discharge may have stopped DAPT due to side effects or bleeding complications 
meaning our estimates of bleeding may be falsely low. Patients admitted near the end of the 
study window may not have reached the end of their DAPT treatment course. 
 
This was an observational analysis and the combinations of DAPT were not randomly assigned. 
We excluded all patients that did not have their antiplatelet therapy recorded in the Prescribing 
Information System database. Due to exclusion of these patients from the analysis, could raise 
the likelihood that the observed effect estimate is biased. We included 33 ACS patients who 
were prescribed with aspirin and dipyridamole, however, we were unable to determine the 
rationale for this treatment decision. We assume it us due to ischaemic stroke.  
 
We lack specific measures of indications for stopping DAPT such as bleeding, switching to 
other antiplatelet, stopping for surgery or lack of adherence. We assume that in most cases 
the cessation of DAPT was planned. Although we could not directly measure medication 
adherence, we did use pharmacy dispensing data, which is strongly correlated with a broad 
range of patient outcomes.20 Use of prescriptions filled has been shown to reflect 
medication use by the patient with a high degree of accuracy.21 We also lack information 
on the type of coronary lesion and the type of stents used in revascularization group. The 
use of over-the-counter medicines were not available22 in this study that could be potential 
confounding factors. Patients in the Scotland receive free prescriptions, which should reduce the 
possibility of over-the-counter medicine use. The present study included patients admitted with 
ACS in the West of Scotland, thus, generalizability to other populations and practice setting is 
unknown. The differences incidence rate between medical and revascularized treated patients in 
the early period did not show a significant difference because of the low number of events in 
each group and the wide confidence intervals. 
 
CONCLUSIONS 
In ACS population, the incidence of cardiovascular events was not higher early post DAPT 
cessation than in later periods. Cardiovascular events post DAPT cessation did occur and were 
associated with increasing age, DAPT duration and lack of revascularization therapy.  
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Table 1: Baseline characteristics whilst on DAPT 
Characteristics 
All patients 
(n=1340) 
Medical treated 
(n=933) 
Revascularization 
treated 
(n=407) 
Age, years    
Mean (SD) 64.9(13.0) 66.7(13.1) 60.9(11.9) 
Median (IQR) 64(55-75) 67(57-77) 60(52-69) 
Sex    
Female 510(38.1) 377(40.4) 133(32.7) 
Male 830(61.9) 556(59.6) 274(67.3) 
Current smoker 296(28.3) 178(25.6) 118(33.4) 
Medical history    
Hypertension 463(34.6) 336(36.0) 127(31.2) 
Diabetes 234(17.5) 157(16.8) 77(18.9) 
Hyperlipidaemia 867(64.7) 591(63.3) 276(67.8) 
CRF 194(14.5) 140(15.0) 54(13.3) 
IHD 323(24.1) 218(23.4) 105(25.8) 
Prior AP therapy    
No prior AP 885(66.0) 576(61.7) 309(75.9) 
Aspirin 316(23.6) 234(25.1) 82(20.1) 
Clopidogrel 35(2.6) 29(3.1) 6(1.5) 
Dipyridamole 6(0.4) 6(0.6) 0(0) 
Aspirin + clopidogrel 59(4.4) 52(5.6) 7(1.7) 
Aspirin + dipyridamole 33(2.5) 30(3.2) 3(0.7) 
Aspirin + ticagrelor 5(0.4) 5(0.5) 0(0) 
DAPT combinations    
Aspirin + clopidogrel 1261(94.2) 861(92.3) 400(98.3) 
Aspirin + dipyridamole 33(2.4) 30(3.2) 3(0.7) 
Aspirin + ticagrelor 42(3.1) 38(4.0) 4(1.0) 
Aspirin + prasugrel 3(0.2) 3(0.3) 0(0) 
Duration of DAPT    
Mean (SD) 175.09(155.30) 164.28(148.17) 199.85(168.10) 
Median (IQR) 113(78-208) 109(76-185) 126(85-311) 
≤ 6 months 955(71.3) 695(74.5) 260(63.9) 
> 6 months 385(28.7) 238(25.5) 147(36.1) 
≤ 12 months 1139(85.0) 812(87.0) 327(80.3) 
> 12 months 201(15.0) 121(13.0) 80(19.7) 
All values are reported as no. (%) unless otherwise noted. Revascularization includes CABG and 
PCI. AP, antiplatelet; CABG, coronary artery bypass graft; CRF, chronic renal failure; DAPT, 
dual antiplatelet therapy; IHD, ischaemic heart disease; PCI, percutaneous coronary intervention; 
SD, standard deviation; IQR, interquartile range.  
Table 2: Incidence of cardiovascular events (composite of death, ACS, transient ischaemic attack or stroke)   
 
During DAPT  After DAPT cessation 
All 
(n=1340) 
Medical 
treated 
(n=933) 
Revascularization 
treated 
(n=407) 
 
All 
(n=1129) 
Medical 
treated 
(n=754) 
Revascularization 
treated 
(n=375) 
Cardiovascular events 211 (15.7) 179 (19.2) 32 (7.9) 
 
188 (16.7) 154 (20.4) 34 (9.1) 
ACS 179 (13.4) 155 (16.6) 24 (5.9)  60 (5.3) 46 (6.1) 14 (3.7) 
Ischaemic stroke/TIA 2 (0.1) 2 (0.2) 0 (0)  24 (2.1) 16 (2.1) 8 (2.1) 
All death 44 (3.3) 35 (3.8) 9 (2.2)  135 (12.0) 120 (15.9) 15 (4.0) 
All values are reported as no. (%) unless otherwise noted. 
Table 3: The risk of cardiovascular eventsa following ACS and up to two years after stopped DAPT 
 
Period, 
days 
All patients Medically-treated Revascularization-treated 
Number 
at risk 
Number 
of events 
Incidence rate  
per 1000 patient-
days  
Number 
at risk 
Number 
of events 
Incidence rate  
per 1000 patient-
days  
Number 
at risk 
Number 
of events 
Incidence rate  
per 1000 patient-
days  
During 
DAPT 
0-90 1340 181 1.882 933 153 2.335 407 28 0.914 
91-180 797 17 0.328 523 15 0.455 274 2 0.106 
181-270 354 5 0.184 209 4 0.255 145 1 0.087 
271-360 250 3 0.152 140 2 0.179 110 1 0.117 
361-450 189 1 0.088 109 1 0.149 80 0 0 
451-540 64 1 0.231 40 1 0.370 24 0 0 
541-630 32 1 0.453 20 0 0.823 12 0 0 
631-720 17 0 0.000 7 2 0 10 0 0 
After DAPT 
cessation 
0-90 1129 15 0.151 754 13 0.199 375 2 0.060 
91-180 1072 22 0.234 706 20 0.325 366 2 0.062 
181-270 1017 21 0.234 660 18 0.311 357 3 0.094 
271-360 978 10 0.115 628 10 0.180 350 0 0.000 
361-450 950 17 0.203 605 14 0.263 345 3 0.100 
451-540 910 16 0.119 577 12 0.237 333 4 0.135 
541-630 876 17 0.220 550 14 0.290 326 3 0.104 
631-720 840 15 0.205 522 10 0.221 318 5 0.179 
aCardiovascular events consist of composite of all-cause mortality, ACS, transient ischaemic attack or stroke. 
  
Table 4: Adjusted incidence rate ratios for the cardiovascular event after DAPT cessation 
Patient 
cohort 
After DAPT cessation (n=1129) 
 
Medical treated 
(n=754) 
 
Revascularization treated 
(n=375) 
n 
Adjusted IRR 
(95% CI) 
p-value 
 
n 
Adjusted IRR 
(95% CI) 
p-value 
 
n 
Adjusted IRR 
(95% CI) 
p-value 
All 
patientsa 
1129 0.79 (0.45-1.42) 0.443 
 
754 0.77 (0.42-1.41) 0.390 
 
375 1.17 (0.13-10.81) 0.889 
All 
patientsb 
1129 0.69 (0.42-1.13) 0.141 
 
754 0.67 (0.39-1.13) 0.133 
 
375 0.79 (0.16-3.87) 0.777 
acomparing the initial 90-day interval versus the 91 to 180-day interval after stopping DAPT. 
bcomparing the initial 90-day interval versus the 91 to 360-day interval after stopping DAPT. 
Cardiovascular events consist of composite of all-cause mortality, ACS, TIA or stroke. All the Poisson regression models (or negative binomial if 
overdispersion is present) adjusted for age, medical or revascularization therapy and duration of DAPT. IRR, incidence rate ratio. 
 Table 5: Univariable and multivariable analyses of possible predictors of cardiovascular events after stopping DAPT  
Predictive variables 
Cox analysis Fine-Gray analysis 
Univariable analysis  Multivariable analysisa Univariable analysis  Multivariable analysisb 
HR 95% CI p-value  
Adjusted 
HR 
95% CI 
p-
value 
SHR 95% CI p-value  SHR 95% CI 
p-
value 
Age 1.08 (1.06-1.09) <0.001  1.07 (1.05-1.08) <0.001 1.04 (1.02-1.06) <0.001  1.02 (1.01-1.05) 0.002 
Male 0.52 (0.39-0.69) <0.001     0.48 (0.30-0.76) 0.002  0.61 (0.38-1.01) 0.053 
Current smoker 1.35 (0.69-2.66) 0.380     1.00 (1.00-1.00) <0.001      
Hypertensionb 3.72 (2.44-5.66) <0.001     1.08 (0.66-1.78) 0.754      
Diabetesb 5.85 (2.75-12.45) <0.001     1.92 (0.88-4.18) 0.099      
Hyperlipidaemiab 1.56 (1.17-2.08) 0.002     1.00 (0.62-1.63) 0.998      
Chronic renal failureb 1.76 (1.08-2.85) 0.023     0.59 (0.34-1.03) 0.063      
Ischaemic heart diseaseb 5.34 (2.97-9.58) <0.001     1.82 (0.96-3.46) 0.065      
Revascularization vs 
medical therapy 
0.38 (0.26-0.55) <0.001  0.58 (0.40-0.85) 0.005 0.63 (0.34-1.06) 0.083      
Prior vs no prior AP 2.02 (1.51-2.70) <0.001     1.94 (1.21-3.09) 0.006      
DAPT duration 0.995 (0.994-0.997) <0.001  0.997 (0.995-0..998) <0.001 0.994 (0.991-0.998) 0.001  0.995 (0.992-0.998) 0.003 
Monotherapy 
Clopidogrel vs aspirin 
1.40 (1.01-1.94) 0.046     1.63 (0.97-2.75) 0.065     
aFinal multivariable analysis. bThese variables were not included in the multivariable analysis due to missing data.  
SHR, subdistribution hazard ratio. 
  
 Figure 1 Flow diagram describing the selection of data for the analysis reported. ACS, acute 
coronary syndrome; AP, antiplatelet; DAPT, dual antiplatelet therapy; SAPT, single antiplatelet 
therapy. 
 Figure 2 Incidence rate (A) during DAPT and (B) after DAPT cessation for patients treated with 
medical and revascularisation therapy. *p<0.01, †p<0.05, compared with patients treated with 
revascularisation therapy from the same interval. ACS, acute coronary syndrome; DAPT, dual 
antiplatelet therapy. 
